PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.13%
EBIT growth of 47.13% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
37.34%
Operating income growth of 37.34% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
47.13%
Net income growth exceeding 1.5x Biotechnology median of 0.01%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
50.90%
EPS growth exceeding 1.5x Biotechnology median of 3.40%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
52.86%
Diluted EPS growth exceeding 1.5x Biotechnology median of 3.63%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
7.67%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
12.32%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
33.57%
OCF growth of 33.57% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
33.08%
FCF growth of 33.08% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9761.92%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-7404.36%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-3986.05%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-11268.60%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-11424.82%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
97.34%
3Y net income/share CAGR of 97.34% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
No Data
No Data available this quarter, please select a different quarter.
7616.79%
5Y equity/share CAGR of 7616.79% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
547.30%
3Y equity/share CAGR of 547.30% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-8.66%
Negative BV/share change while Biotechnology median is -4.68%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-100.00%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-26.31%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-49.44%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.